All participants will be asked to take Lapatinib daily for a total of six months during the research study.

All participants will be asked to take Lapatinib daily for a total of six months during the research study.
Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.

Lapatinib

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Prolactin

Tumor volume will be assessed on MRI at 6 months on therapy and compared to baseline MRI.

All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study.
Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.

Change in Tumor Volume

50% reduction in prolactin level measured monthly on 6 months therapy compared to baseline level.

Number of Participants With 50% Reduction in Prolactin Levels

Percent prolactin change from start of lapatinib to end of study participant participation

% Change in Prolactin From Baseline to Study End

Mean percent positive expression of EGFR and ErbB2 will be tested on pathologic tumor specimens from subjects treated with lapatinib

ErbB Receptor Expression

Overall Study

Odelia Cooper

Pituitary Adenomas

Prolactinomas

All participants will be asked to take Lapatinib daily for six months during the research study.

prolactinoma/tyrosine

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

The most complete medicinal herbs database backed by science